@article{fdi:010094237,
  title = {{P}re- and post-vaccination measles antibody and persistence up to 5 years of age among early {ART}-treated {HIV}-infected, {HIV}-exposed {U}ninfected and {HIV}-unexposed children in {C}ameroon},
  author = {{T}ejiokem, {M}. {C}. and {D}esselas, {E}milie and {N}oumsi, {T}. {J}. and {N}dongo, {F}. {A}. and {N}diang, {S}. {T}. and {F}ossi, {M}. {A}. and {G}uemkam, {G}. and {T}ekougang, {B}. {Z}. {K}. and {T}agnouokam-{N}goupo, {P}. {A}. and {P}enda, {I}. {C}. and {F}aye, {A}. and {W}arszawski, {J}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground/{O}bjective: {V}ariations in measles vaccine antibody response by age and {HIV} status have been reported. {T}his study assessed measles pre-vaccination status and compared humoral response durability over the first five years of life among {HIV}-infected ({HI}) children on early treatment, {HIV}-exposed uninfected ({HEU}), and {HIV}-unexposed uninfected ({HUU}) children within the {ANRS} 12225-{P}ediacam {III} cohort in {C}ameroon. {M}ethods: {M}easles vaccine ({MCV}) was administered at 6 and 9 months for {HIV}-exposed infants and at 9 months for {HIV}-unexposed infants, followed by a measles-mumps-rubella ({MMR}) dose at 15 months for all. {M}easles antibody titers were measured pre-vaccination, 1-6 months post-{MCV} doses, and annually until age 5 using {ELISA} ({E}nzygnost, {D}ade {B}ehring). {R}esults: {A} total of 496 children were included: 143 {HI} (median age at c{ART} initiation: 4.2 months, ({IQR}: 3.2-5.6)), 180 {HEU}, and 173 {HUU}. {O}f these, 456 children were tested pre-vaccination (median age: 6.1 months, {IQR}: 5.6-6.8), with 6.1% (95% {CI}: 4.1-8.6) seropositive to measles antibodies, with differences across groups. {A}t 18.4 months ({IQR}: 18.1-19.9), seropositivity rates were 96.7% (59/61) in {HI}, 96.8% (90/93) in {HEU}, and 100% (111/111) in {HUU} groups. {F}or children following the 6 + 9 + 15-month or 9 + 15-month {MCV} schedules, seropositivity at 18, 36, 48, and 60 months was 96%, 89%, 87%, and 88%, respectively, with no significant differences between groups. {C}onclusions: {E}arly c{ART} initiation in {HI} children may result in a robust initial measles antibody response, with comparable persistence of antibody titers across all groups up to five years.},
  keywords = {measles humoral immunity ; persistence of measles antibodies ; pre-measles ; vaccine antibodies ; early treated {HIV}-infected ; {HIV}-exposed uninfected ; {HIV}-unexposed uninfected ; low- and middle-income countries ; real life conditions ; {CAMEROUN}},
  booktitle = {},
  journal = {{V}accines},
  volume = {13},
  numero = {6},
  pages = {584 [16 p.]},
  year = {2025},
  DOI = {10.3390/vaccines13060584},
  URL = {https://www.documentation.ird.fr/hor/fdi:010094237},
}